1,240 filings
F-3ASR
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
S-8
SNY
Sanofi
4 Apr 24
Registration of securities for employees
8:45am
6-K
SNY
Sanofi
20 Mar 24
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
2:07pm
S-8 POS
SNY
Sanofi
15 Mar 24
Registration of securities for employees (post-effective amendment)
8:40am
6-K
SNY
Sanofi
27 Feb 24
Current report (foreign)
11:35am
IRAN
SNY
Sanofi
23 Feb 24
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
2:02pm
6-K
SNY
Sanofi
15 Feb 24
Current report (foreign)
12:09pm
SC 13G/A
Amundi
14 Feb 24
Sanofi / Amundi ownership change
3:57pm
SC 13G/A
Dodge & Cox
13 Feb 24
Sanofi / DODGE & COX ownership change
1:55pm
SC 13G/A
BLK
Blackrock Inc.
6 Feb 24
Sanofi / BlackRock ownership change
3:14pm
6-K
SNY
Sanofi
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
6-K
SNY
Sanofi
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
6-K
SNY
Sanofi
23 Jan 24
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
7:23am
6-K
SNY
Sanofi
17 Jan 24
Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
1:49pm
6-K
SNY
Sanofi
27 Dec 23
Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
11:18am
6-K
SNY
Sanofi
20 Dec 23
Current report (foreign)
10:39am
F-6EF
JPMorgan Chase Bank, N.A. - ADR Depositary
18 Dec 23
Automatic registration for ADRs (foreign)
5:23pm
6-K
SNY
Sanofi
1 Dec 23
Current report (foreign)
12:19pm
SC 13G
MGTX
MeiraGTx Holdings plc
6 Nov 23
MeiraGTx / Sanofi ownership change
7:50am
6-K
SNY
Sanofi
27 Oct 23
Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
12:39pm